Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6952/296_v5_Ibrutinib_CLL_WM.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. 3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) TP53 somatic variants Chronic Lymphocytic Leukemia Ibrutinib
HSE (1) TP53 deletion Chronic Lymphocytic Leukemia Ibrutinib
HSE (1) 17p deletion Chronic Lymphocytic Leukemia Ibrutinib